A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * Participants must have histologically confirmed salivary gland carcinoma (any histologic subtype, including ACC) with evidence of recurrent, metastatic, or advanced, unresectable disease. * Willing to provide tumor tissue from a diagnostic biopsy or prior surgery if deemed safe and feasible by the investigator. * Age 18 years or older at the time of consent. There is no upper age limit restriction in an effort to include patients across the lifespan. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Participant must have organ and marrow function as defined below within 14 days prior to study registration: * Absolute neutrophil count (ANC) ≥1000/mcL * Hemoglobin ≥8.5 g/dL (with no blood transfusions within 7 days of start of therapy) * Platelets ≥100,000/mcL * Liver function: * Serum total bilirubin (T-bili) ≤1.5× upper limit of normal (ULN); for patients with liver metastases or confirmed/suspected Gilbert syndrome, T-bili ≤3…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source